Pressure BioSciences, Inc. Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences

May 05, 2014, 08:49 ET from Pressure BioSciences, Inc.

SOUTH EASTON, Mass., May 5, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a worldwide leader in the development and sale of high pressure-based sample preparation systems to the life sciences research market, today announced that it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 New York, NY.  The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.  To accomplish this mission, the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts, and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis, and treatment.

Mr. Michael Moffat, Cavendish co-founder and President explains, "With the help of our expert advisors, we conducted a global search of research institutions and private-sector companies to identify organizations that meet the required standard of excellence.  The quality and originality of Pressure BioSciences' broadly enabling pressure cycling technology (PCT) platform positions them to make major contributions in supporting thousands of researchers around the world in their efforts to identify, control, prevent, and cure a host of diseases and disorders afflicting humans, animals, and plants."

"We are honored to be selected to present at this unique event, as we believe it is further recognition of the importance of our powerful and innovative PCT platform," said Mr. Richard T. Schumacher, President and CEO of PBI.  "Over 100 publications now cite the advantages of the PCT System in the development of improved testing methods to enhance the health and well-being of people worldwide.  These methods are used in areas such as (i) human disease and disorders, (ii) forensics, (iii) food safety, and (iv) agriculture.  We welcome the opportunity to interact with many of world's leading scientific minds, thought-leaders, and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people worldwide."

Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making, and impact investing.  The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.  Cavendish Global, together with the Global Partnerships Forum and the New York Academy of Sciences, organizes the Forum annually in New York.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.      

Further information is available on the Company's website:

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States (taking place in New York at the United Nations Headquarters May 5th to 7th 2014), Europe (London, October 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015).

For more information:

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Investor Contacts:

Richard T. Schumacher, President and CEO                           (508) 230-1828 (T)
Richard P. Thomley, CFO                                                      (508) 230-1829 (F)
Howard Gostfrand, President, American Capital Ventures         (305) 918-7000 (T)

SOURCE Pressure BioSciences, Inc.